Evommune Licenses Hinova Autoimmune Drug in Deal Worth Up to $1.1 Billion
Evommune said it licensed rights to an experimental autoimmune disease treatment from China's Hinova Pharmaceuticals, with up to about $1.1 billion in milestone payments.
Evommune NYSE:EVMN said on Wednesday it had licensed rights to an experimental autoimmune disease treatment from China's Hinova Pharmaceuticals SSE:688302 in a deal worth up to about $1.1 billion in milestone payments.Here are some details